Results 41 to 50 of about 81,076 (308)
Intracellular mechanisms underlying the nicotinic enhancement of LTP in the rat dentate gyrus [PDF]
We have previously shown that activation of nicotinic acetylcholine receptors (nAChRs) enhanced long-term potentiation (LTP) in the rat dentate gyrus in vitro via activation of α7 nAChR. In the present studies, mechanisms underlying the acute and chronic
Abel +81 more
core +1 more source
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel +2 more
core +1 more source
Janus kinase inhibitors: between prescription authorization and reimbursability
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.
F.R. Spinelli +5 more
openaire +5 more sources
Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19
Objectives: Intracerebral hemorrhage/bleeding (ICH) after an infection with SARS-CoV-2 (COVID-19) treated with the Janus-kinase inhibitor baricitinib has not been reported.
Josef Finsterer, Fulvio A. Scorza
doaj +1 more source
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death [PDF]
BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that arise most commonly in the setting of the Neurofibromatosis Type 1 (NF1) cancer predisposition syndrome.
Bu, Xianzhang +7 more
core +2 more sources
Background Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation.
Katya Prakash, Douglas Richman
doaj +1 more source
Primary Myelofibrosis-Related Renal Disorders Treated with a Janus Kinase Inhibitor
Extramedullary hematopoiesis is widely known to occur in patients with primary myelofibrosis (PMF). Autopsy studies on individuals with PMF revealed that extramedullary hematopoiesis occurred in the kidneys in 35% of the cases, but there is little ...
Mea Asou +5 more
doaj +1 more source
Targeting STAT3 in Cancer with Nucleotide Therapeutics. [PDF]
Signal transducer and activator of transcription 3 (STAT3) plays a critical role in promoting the proliferation and survival of tumor cells. As a ubiquitously-expressed transcription factor, STAT3 has commonly been considered an "undruggable" target for ...
Grandis, Jennifer R +3 more
core +2 more sources
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source
MTOR cross-talk in cancer and potential for combination therapy [PDF]
The mammalian Target of Rapamycin (mTOR) pathway plays an essential role in sensing and integrating a variety of exogenous cues to regulate cellular growth and metabolism, in both physiological and pathological conditions.
Bazzichetto, C. +7 more
core +3 more sources

